Louis J. Winthorpe is lead analyst spearing the leverage buyout. Billy J Valentine is representing the firm of Duke and Duke. GLTA
They are charging too damn much when the alternatives are cheaper and work just as good. GLTA
Jealously, revenge and untruth will wear on the mind and body and he will eventually pass away of an early death due to some disease that there is a drug for but he will refuse to take because he previously slammed the company. How sad.
This guy is a real piece of work. Everyone runs around like he is some god or something. Directors have every right to do what they have done. You invest in a company for the product and its results not some directors buy and sell plans on any given stock. good grief. Spread your risk and you will be ok. This is only a very small part of my overall plan. GLTA
This stock will rocket one day out of the blue then you will be damned if you sold. GLTA
The market is gonna be flooded with drugs to either cure, alter, slow down CLL and other blood disorders. Pick the right stock and win big.
U will see
Thank you for a proven product.
Proven company and drug delivery. GLTA. Manipulation is such a downer isn't it.
Hold under earnings get reported and guidance will be validated. GLTA
GLTA See NWBO. Prime example. Also an opportunity to enter NWBO on sale. GLTA
This is a gem for another company to pounce on. GLTA
Holding until double digits.
R&D was paid for by CELERA company before Pharmacyclics acquired it doofus. Only this PCYC is paying for is testing on patients and clinical trials which is not as expensive as actual DRUG DEVELOPMENT. Get a clue pal. Anyways there will be some many alternatives out there soon that PCYC will have to drop its price.
As usual. Guess those in need will have to wait until others drugs are approved. This is way too overpriced and many will die rather than go into debt. So sad. Duggan should get a clue.